PainReform (NASDAQ:PRFX) Trading Down 4.6% – What’s Next?

Shares of PainReform Ltd. (NASDAQ:PRFX) traded down 4.6% on Friday . The company traded as low as $2.05 and last traded at $2.09. 24,438 shares were traded during mid-day trading, a decline of 98% from the average session volume of 1,099,296 shares. The stock had previously closed at $2.19.

PainReform Price Performance

The company has a market cap of $1.83 million, a P/E ratio of -0.01 and a beta of 0.72. The firm’s 50-day moving average is $2.90 and its two-hundred day moving average is $2.98.

Institutional Trading of PainReform

A hedge fund recently bought a new stake in PainReform stock. Apollon Wealth Management LLC acquired a new position in shares of PainReform Ltd. (NASDAQ:PRFX) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 12,917 shares of the company’s stock, valued at approximately $43,000. Apollon Wealth Management LLC owned about 9.23% of PainReform at the end of the most recent reporting period. 37.28% of the stock is currently owned by institutional investors and hedge funds.

PainReform Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.